The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease

BMC Nephrology

Muhammad Magdi Yaqoob²  Alistair Chesser²  Ellena Badrick¹  Gavin Dreyer²  Sally Hull¹ 

[1] Centre for health sciences, Queen Mary University,London, UK;Renal Department, Barts and the London NHS trust, London, UK

关键词: ethnicity;    hypertension;    eGFR;    chronic kidney disease;    blood pressure;   

Others  :  1083242
DOI  :  10.1186/1471-2369-12-41

 received in 2011-03-15, accepted in 2011-09-06,  发布年份 2011

【 摘 要 】

Background

The effect of ethnicity on the prevalence and management of hypertension and associated chronic kidney (CKD) disease in the UK is unknown.

Methods

We performed a cross sectional study of 49,203 adults with hypertension to establish the prevalence and management of hypertension and associated CKD by ethnicity. Routinely collected data from general practice hypertension registers in 148 practices in London between 1/1/07 and 31/3/08 were analysed.

Results

The crude prevalence of hypertension was 9.5%, and by ethnicity was 8.2% for White, 11.3% for South Asian and 11.1% for Black groups. The prevalence of CKD stages 3-5 among those with hypertension was 22%. Stage 3 CKD was less prevalent in South Asian groups (OR 0.77, 95% CI 0.67 - 0.88) compared to Whites (reference population) with Black groups having similar rates to Whites. The prevalence of severe CKD (stages 4-5) was higher in the South Asian group (OR 1.53, 95% CI 1.17 - 2.0) compared to Whites, but did not differ between Black and White groups. In the whole hypertension cohort, achievement of target blood pressure (< 140/90 mmHg) was better in South Asian (OR 1.43, 95% CI 1.28 - 1.60) and worse in Black groups (OR 0.79, 95% CI 0.74 - 0.84) compared to White patients. Hypertensive medication was prescribed unequally among ethnic groups for any degree of blood pressure control.

Conclusions

Significant variations exist in the prevalence of hypertension and associated CKD and its management between the major ethnic groups. Among those with CKD less than 50% were treated to a target BP of ≤ 130/80 mmHg. Rates of ACE-I/ARB prescribing for those with CKD were less than optimal, with the lowest rates (58.5%) among Black groups.

【 授权许可】

   
2011 Hull et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
• [2]Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334:13-18.
• [3]The National Service Framework for Renal Services - Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care. 2005. Last accessed 1/12/09.http://www.kidney.org.uk/campaigns/Renal-nsf/nsf-pt2.pdf webcite
• [4]Chronic Kidney Disease in Adults: UK Guidelines for Identification, Management and Referral. Joint Specialty Committee on Renal Medicine of the Royal College of Physicians and the Renal Association and the Royal College of General Practitioners 2006. Last accessed 3/1/10. http://www.kidney.org.uk/campaigns/Renal-nsf/nsf-pt2.pdf webcite
• [5]K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification Am J Kidney Dis 2002, 39:S1-S266.
• [6]Peralta CA, Hicks LS, Chertow GM, Ayanian JZ, Vittinghoff E, Lin F, Shlipak MG: Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005, 45:1119-1124.
• [7]Ansell DFJ, Feest TG, et al.: UK Renal Registry Report. [http://www.renalreg.com/] webcite 2007.
• [8]Quality and Outcome Framework [http://www.primarycarecontracting.nhs.uk/145.php] webcite
• [9]Millett C, Gray J, Bottle A, Majeed A: Ethnic disparities in blood pressure management in patients with hypertension after the introduction of pay for performance. Ann Fam Med 2008, 6:490-496.
• [10]Ashworth M, Medina J, Morgan M: Effect of social deprivation on blood pressure monitoring and control in England: a survey of data from the quality and outcomes framework. BMJ 2008, 337:a2030.
• [11]Falaschetti E, Chaudhury M, Mindell J, Poulter N: Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009, 53:480-486.
• [12]Primatesta P, Bost L, Poulter NR: Blood pressure levels and hypertension status among ethnic groups in England. J Hum Hypertens 2000, 14:143-148.
• [13]Mathur R, Hull SA, Badrick E, Robson J: Cardiovascular multimorbidity: the effect of ethnicity on prevalence and risk factor management. Br J Gen Pract 2011, 61:262-270.
• [14]Dreyer G, Hull S, Aitken Z, Chesser A, Yaqoob MM: The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. QJM 2009, 102:261-269.
• [15]Office for National Statistics [http://www.ons.gov.uk/] webcite
• [16]Clinical effectiveness group [http://www.ihse.qmul.ac.uk/chs/ceg/index.html] webcite
• [17]de Lusignan S, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, Van Vlymen J, Walker M, Hilton S: Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005, 22:234-241.
• [18]Clinical Terms (the Read codes) Version 3 Reference manual Accessed Jan 27 2010. http://www.connectingforhealth.nhs.uk/systemsandservices/data/readcodes webcite
• [19]Feehally J, Griffith KE, Lamb EJ, O'Donoghue DJ, Tomson CR: Early detection of chronic kidney disease. BMJ 2008, 337:a1618.
• [20]GLA 2007 Round Demographic Projections Greater London Authority Data Management and Analysis Group 2008. Last accessed 1/12/09. http://legacy.london.gov.uk/gla/publications/factsandfigures/dmag-briefing-2008-07.pdf webcite
• [21]Stata [http://www.stata.com] webcite
• [22]Hypertension management in adults in primary care: pharmacological update National Institue for Clinical Excellence Guidelines 2004. Last accessed 1/12/09. http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf webcite
• [23]Campbell SM, Reeves D, Kontopantelis E, Sibbald B, Roland M: Effects of pay for performance on the quality of primary care in England. N Engl J Med 2009, 361:368-378.
• [24]Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J: Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002, 13:2776-2782.
• [25]Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group JAMA 1991, 265:3255-3264.
• [26]Ekbom T, Linjer E, Hedner T, Lanke J, De Faire U, Wester PO, Dahlof B, Schersten B: Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 2004, 13:137-141.
• [27]Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, et al.: Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998, 158:741-751.
• [28]Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
• [29]Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
• [30]Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
• [31]Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW: Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009, 75:736-745.
• [32]Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, et al.: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40:1185-1192.
• [33]van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000, 342:1-8.
• [34]Nasser SA, Lai Z, O'Connor S, Liu X, Flack JM: Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr Hypertens Rep 2008, 10:398-404.
• [35]Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S: Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4:1565-1574.
• [36]Othman M, Kawar B, El Nahas AM: Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract 2009, 113:c16-23.